Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,753 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 2 Interventional

Therapy of Early Chronic Phase CML With Gleevec

NCT00048672
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
Gleevec
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Results available

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

NCT03897036
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
CX-4945
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Sublingual Fentanyl for the Management of Breakthrough Pain

NCT02514252
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests, Study Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study

NCT06085326
View directory record Official record
Conditions
Intubation Complication
Interventions
Smart Checklist
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 19 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety: R33 Phase

NCT07818876
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Cognitive Bias Modification for Interpretations (CBM-I), Cognitive Restructuring (CR)
Other
Lead sponsor
University of Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

NCT00574145
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue
Interventions
Bio-field energy therapy, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment, therapeutic touch
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 3 Interventional Results available

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

NCT01924845
View directory record Official record
Conditions
Late-onset Pompe Disease
Interventions
BMN 701
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole in Patients With Pulmonary Arterial Hypertension

NCT01545336
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Phase 1 Interventional

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

NCT06586255
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Bladder Cancer
Interventions
Concurrent Immunotherapy and Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Phase 4 Interventional

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

NCT05183126
View directory record Official record
Conditions
Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Interventions
Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

NCT02206087
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, Heparin Sodium
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

NCT02650804
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BPM31510 Nanosuspension Injection, Gemcitabine
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

NCT05895552
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RTA 901, RTA 901-Matching Placebo
Drug
Lead sponsor
Reata, a wholly owned subsidiary of Biogen
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
75
States / cities
Mesa, Arizona • Phoenix, Arizona • Canoga Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway

NCT01499940
View directory record Official record
Conditions
Neurotoxicity
Interventions
Vitamin D3
Drug
Lead sponsor
Gerald Higa, PharmD.
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 28, 2026, 5:06 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions
rQNestin, Cyclophosphamide, Stereotactic biopsy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Examining Transcutaneous Vagal Nerve Stimulation as a Facilitator of Social Bonding

NCT05899413
View directory record Official record
Conditions
Vagus Nerve Stimulation
Interventions
Transcutaneous vagal nerve stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 39 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 28, 2026, 5:06 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Rhode Island Asthma Integrated Response Program

NCT03583814
View directory record Official record
Conditions
Asthma in Children
Interventions
CASE Program, HARP Program
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
2 Years to 12 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms in Postmenopausal Women

NCT04893226
View directory record Official record
Conditions
Metabolic Syndrome, Postmenopausal Symptoms
Interventions
Time-Restricted Feeding (TRF)
Behavioral
Lead sponsor
Julie Pendergast
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

NCT01142232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Veterans Response to Dosage in Chiropractic Therapy

NCT04087291
View directory record Official record
Conditions
Low Back Pain, Patient Acceptance of Health Care, Veterans Health
Interventions
Chiropractic Care
Other
Lead sponsor
Palmer College of Chiropractic
Other
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Los Angeles, California • West Haven, Connecticut • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects

NCT02015390
View directory record Official record
Conditions
Segmental Long Bone Defects
Interventions
Autogenous RIA bone grafting, Allogeneic bone grafting
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 28, 2026, 5:06 PM EDT